Lewy Body Dementia (LBD) is a progressive neurological disorder caused by abnormal protein clumps called Lewy bodies that accumulate in brain cells, triggering cognitive decline, movement problems, and sleep disturbances. Visual hallucinations are among its most distinctive features—occurring in roughly 6 out of 10 people diagnosed with the condition. A person with LBD might see animals, people, or elaborate scenes that feel completely real, even when no one else in the room observes them.
These aren’t dreams or delusions; they’re a direct result of how Lewy bodies damage the visual processing regions of the brain. LBD ranks as the second most common cause of neurodegenerative dementia after Alzheimer’s disease and represents the third most common type of dementia overall, affecting between 10 and 25 percent of all dementia cases in America. Despite this prevalence, many families and physicians are unfamiliar with the condition, often confusing it with Parkinson’s disease or Alzheimer’s, which delays diagnosis and appropriate care. Understanding what LBD is and how its visual hallucinations develop is critical for anyone involved in dementia care.
Table of Contents
- What Is Lewy Body Dementia and How Common Is It?
- Visual Hallucinations in Lewy Body Dementia—More Than Just a Side Effect
- The Brain Changes Behind Visual Hallucinations
- DLB versus Parkinson’s Disease Dementia—When Cognitive or Motor Symptoms Come First
- The Pathological Overlap with Alzheimer’s Disease
- Psychiatric Symptoms and Depression in LBD
- Active Clinical Trials and Emerging Treatments
What Is Lewy Body Dementia and How Common Is It?
Lewy Body Dementia comprises two related conditions distinguished by the timing of symptoms: Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD). In DLB, cognitive impairment—problems with thinking, memory, and reasoning—precedes or occurs alongside motor symptoms like tremor and stiffness within the first year. In PDD, cognitive decline appears more than a year after motor symptoms have already begun. This distinction matters for diagnosis because a person arriving at a clinic with memory loss might receive a dementia diagnosis first, while another with a tremor history might first receive a Parkinson’s diagnosis and only later show cognitive changes.
The numbers are significant. LBD affects an estimated 1 to 2 percent of the population aged 65 and older, with an incidence rate of 7.10 per 100,000 person-years. The average age at diagnosis is 76.3 years, and the condition is more common in men than women. Because the oldest populations are also the fastest-growing demographic, more families will encounter LBD in the coming decade. Yet many primary care doctors and even some neurologists see fewer than a handful of LBD cases annually, making accurate diagnosis a persistent challenge.
Visual Hallucinations in Lewy Body Dementia—More Than Just a Side Effect
Visual hallucinations occur in approximately 62 percent of DLB patients, though the range varies from study to study. What makes this figure striking is how much more common visual hallucinations are in LBD compared to other dementias; they appear in only about 15 percent of early Alzheimer’s cases and are rare in frontotemporal dementia. Women with LBD experience visual hallucinations at slightly higher rates (60 percent) than men (45 percent), and the hallucinations can be frequent—some people report seeing them daily, while others encounter them a few times per week. The hallucinations themselves tend to be recurrent and specific.
A person might repeatedly see small animals, such as cats or dogs, sitting in a chair, or they might witness people moving through their home. Some report seeing entire scenes—a parade, a marketplace, children playing. Unlike the fleeting images in a dream, these visions persist while the person is awake and alert, can describe them in detail, and often react emotionally to what they see, even though they may gradually learn the images aren’t real. A critical limitation: hallucinations can distress both the person experiencing them and their caregivers, and some antipsychotic medications commonly used for hallucinations in other conditions can worsen motor symptoms in LBD, requiring careful medication selection.
The Brain Changes Behind Visual Hallucinations
Visual hallucinations in LBD arise from lewy body accumulation in regions of the brain responsible for processing visual information, including the visual cortex and areas involved in attention and perception. When these pathways are damaged, the brain generates images without external sensory input, much as it does during dreams—but the person is conscious and alert. This mechanism explains why reassurance or logical argument rarely eliminates the hallucination; the person isn’t confused about reality, but their brain’s visual system is malfunctioning.
Recent research from 2024 found that early Lewy body pathology appears in the olfactory bulb—the smell-processing structure in the brain—in 82 percent of individuals studied, suggesting that the disease begins in sensory regions and may spread outward to affect vision, cognition, and movement. This distributed damage helps explain why LBD often combines hallucinations with other sensory and motor problems, and why symptoms can vary widely from person to person depending on which brain areas are most affected. Understanding this distribution is essential because it means that hallucinations alone don’t predict how severe cognitive or movement problems will be—someone with vivid visual hallucinations might have relatively mild memory loss, or vice versa.
DLB versus Parkinson’s Disease Dementia—When Cognitive or Motor Symptoms Come First
The distinction between DLB and PDD hinges on whether cognitive symptoms or motor symptoms appear first. In DLB, a person typically notices problems with memory, thinking, or attention before developing Parkinson-like movement issues. In PDD, the diagnosis of Parkinson’s disease is already established—often years prior—before cognitive decline emerges. Both conditions involve Lewy bodies and can cause visual hallucinations, but the disease progression and treatment priorities differ. A practical example illustrates the difference: a 78-year-old woman visits her doctor because she’s having trouble balancing her checkbook and feels confused at times.
Within months, she develops a slight tremor and stiffness. Her diagnosis is DLB. Contrast this with a 75-year-old man who had a Parkinson’s diagnosis three years ago, managed with levodopa, and now is beginning to have memory lapses and trouble planning. His diagnosis becomes Parkinson’s Disease Dementia. The same pathology—Lewy bodies—drives both conditions, but the entry point to diagnosis differs, which can affect how aggressively cognitive changes are investigated and how motor and cognitive medications are balanced.
The Pathological Overlap with Alzheimer’s Disease
A complicating factor in LBD diagnosis and prognosis is that many people with LBD also harbor Alzheimer’s disease pathology. Between 50 and 80 percent of LBD patients have concomitant accumulation of amyloid-beta and tau proteins—the hallmark pathologies of Alzheimer’s disease—found in their brains at autopsy or on advanced imaging. This overlap means a person might be experiencing cognitive decline, hallucinations, and movement problems driven by multiple protein accumulations simultaneously. At the other end of the spectrum, autopsy studies show that 40 percent of Parkinson’s disease patients—many of whom never developed dementia clinically—exhibit enough amyloid-beta and neurofibrillary tangles to meet pathological criteria for Alzheimer’s disease.
This mixed pathology creates a diagnostic and prognostic challenge. A person diagnosed with DLB based on cognitive decline and hallucinations might also have silent Alzheimer’s pathology that worsens cognitive decline faster than LBD alone would predict. Conversely, someone with Parkinson’s disease might have substantial Alzheimer’s-level pathology that has not yet crossed the threshold into clinical cognitive impairment. Genetic and molecular studies show that LBD shares genetic profiles with both Parkinson’s disease and Alzheimer’s disease, indicating that these conditions operate on overlapping biological pathways rather than as entirely distinct diseases.
Psychiatric Symptoms and Depression in LBD
Depression is emerging as a critical feature of LBD, particularly in early stages. A 2024 study found that depression was the most common psychiatric symptom, present in 88 percent of people at the time of LBD onset and in 100 percent during the prodromal (pre-symptom) stage. This means depression often appears before memory loss or hallucinations become obvious, making early detection difficult.
Families often attribute mood changes to normal aging or stress, missing the opportunity for early intervention. The prevalence of depression in LBD significantly exceeds that in Alzheimer’s disease at comparable stages, yet the high rates remain underrecognized and undertreated. Depression can amplify cognitive symptoms, worsen hallucinations, and complicate medication management, since some antidepressants and other psychiatric drugs interact unpredictably with Parkinson-like motor symptoms in LBD.
Active Clinical Trials and Emerging Treatments
Research into LBD treatment is advancing, with multiple clinical trials underway as of 2026. Neflamapimod, a P38 alpha kinase inhibitor, has progressed through Phase 2b trials completed in June 2025 and a Phase 2a open-label study completed in March 2026.
These trials aim to slow cognitive and motor decline by addressing the protein misfolding cascade that leads to Lewy body formation. Additionally, the Find-DLB study, based at the Karolinska Institutet and recruiting through 2031, is enrolling participants to better characterize disease progression and identify early biomarkers that could enable diagnosis before significant brain damage occurs. These efforts reflect a growing recognition that earlier diagnosis and intervention are necessary to improve outcomes in LBD.
- —
